Favoxil

Quick links to important sections

Favoxil

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Favoxil

Property Description
Active ingredient Fluvoxamine Maleate
Form Oral tablets, Extended-release capsules
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Unique Feature Potent sigma1 receptor agonist activity
Origin Synthetic compound

What Type of Medicine is Favoxil (Fluvoxamine)?

Favoxil is a synthetic prescription medication chemically classified as an antidepressant and specifically categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). The pharmaceutical entity contains Fluvoxamine Maleate as its sole active ingredient, confirming it is a single-ingredient product. This classification places Fluvoxamine within a modern category of psychotropic agents that target specific chemical pathways. Fluvoxamine is used in the clinical management of conditions characterized by intrusive, persistent thoughts and repetitive behaviors. Notably, the drug possesses unique affinity as a potent agonist at the sigma1 receptor, a secondary action that contributes to its distinct pharmacological profile compared to many other SSRIs.


Composition and Available Oral Forms

The core composition of Favoxil consists of the active substance, Fluvoxamine Maleate, combined with various inert excipients required for safe and effective oral route delivery. Fluvoxamine is manufactured in solid oral dosage forms, specifically as film-coated tablets and specialized extended-release capsules. The existence of an extended-release option, often marketed under the brand name Luvox CR, is a structural design intended to control the rate at which Fluvoxamine is dissolved and absorbed into the bloodstream. This controlled delivery provides a smoother, more consistent release profile than the immediate-release tablet formulation.


The General Purpose of Fluvoxamine's Action

The general purpose of Fluvoxamine is to help modulate emotional stability by correcting functional chemical imbalances related to neurotransmitter activity. As an SSRI, its function is the highly specific inhibition of neuronal serotonin reuptake, meaning it prevents nerve cells from rapidly absorbing serotonin (5-HT) after its release. This action results in a sustained, higher concentration of serotonin available in the synaptic space, which aims to modulate mood, address severe persistent worry, and support the neural circuits governing emotional responses.

Regulatory References

  1. Fluvoxamine Maleate monograph on NIH (DailyMed)
  2. NIH MedlinePlus Fluvoxamine Information

What side effects are possible with Favoxil?

Possible Side Effects and Safety Information

The safety profile of Fluvoxamine Maleate is established through the formal classification of adverse reactions and specific safety statements documented by regulatory health authorities. Adverse events are grouped by both the physiological system affected (System-Organ Class) and their reported frequency in clinical studies.

Reactions classified as Very Common (occurring in 10% or more of patients) include Nausea. Common adverse effects (occurring in 1% to <10%) frequently involve the gastrointestinal and nervous systems, encompassing reactions such as Insomnia, Somnolence, Headache, Tremor, Dry Mouth, Diarrhea, Vomiting, Anorexia, and Abnormal ejaculation.

Less frequent reactions, such as Convulsion, Mania, and Abnormal hepatic function, are documented as Rare in official texts. Uncommon effects include Hallucination and Orthostatic hypotension.

Clinically Significant Safety Considerations

The official labeling highlights several serious safety concerns that warrant attention. These include the risk of Serotonin Syndrome, which can occur, especially when Fluvoxamine is used alongside other serotonergic agents. An increased risk for Abnormal Bleeding is also noted, particularly with the concomitant use of drugs affecting blood clotting. Other serious events include the potential for Hyponatraemia (low sodium in the blood) and the activation of Mania or Hypomania.

Population and Time-Related Notes

Safety statements are specific to certain groups and treatment phases. In children, adolescents, and young adults, an increased risk of Suicidal Ideation and Behavior is noted, with this risk being highest during the initial months of therapy and following dose changes. Akathisia (restlessness) is documented as most likely to occur within the first few weeks of treatment. Older patients may be at an increased risk for Hyponatraemia.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Fluvoxamine Maleate is officially documented to present with a range of manifestations, including common effects such as gastrointestinal issues (vomiting, diarrhea), and neurological signs like drowsiness, agitation, and confusion. Severe outcomes formally listed in regulatory documents include life-threatening events such as seizures, coma, and respiratory arrest. Cardiovascular disturbances, including tachycardia (fast heartbeat) and ECG abnormalities, have also been reported as potential complications arising from an overdose.

Government guidance explicitly mandates seeking immediate medical attention for suspected overdose. Urgent contact with emergency services is required if the individual collapses, has trouble breathing, or is unresponsive. Management is officially described as symptomatic and supportive. This may involve procedures like maintaining an open airway and continuous monitoring of vital signs and ECG. Regulatory information states that no specific antidote is known to reverse the effects of Fluvoxamine. A specific consideration noted in official documentation is the increased potential for hyponatremia (low sodium in the blood) in the elderly population following overdose.

Therapeutic Uses of Favoxil

Favoxil is commonly used to assist with managing groups of symptoms associated with Obsessive-Compulsive Disorder (OCD), which may manifest as persistent, distressing intrusive thoughts (obsessions) and subsequent repetitive, ritualistic actions (compulsions). This medication is applicable in conditions characterized by periods of heightened symptoms and is also used for the management of certain Anxiety Disorders, including Social Anxiety Disorder.

This treatment is applied in clinical settings that involve acute or unstable symptom patterns where functional stability has become affected. The medication is applied in situations where patients experience persistent manifestations, and it may provide supportive relief that helps ease the overall symptom burden, which can contribute to improved day-to-day comfort.

“The medication is considered relevant in contexts marked by increased discomfort or tension, assisting with maintaining functional stability.”

Quick Fact: Relief for Obsessions and Compulsions Favoxil is commonly used to help manage the intensity of recurrent, intrusive thoughts and the subsequent ritualistic behaviors that create noticeable physiological strain, which may assist patients with maintaining functional stability during symptom fluctuations.


Alleviating Chronic Anxiety and Repetitive Urges

Favoxil may be considered relevant in contexts marked by increased discomfort or tension associated with certain Anxiety Disorders. It may assist with managing the excessive, chronic worry and intense avoidance behaviors, which can often interfere with daily functioning. Furthermore, the drug is applied across domains where additional symptomatic support is needed to help manage pathological urges and related repetitive behaviors that may create significant functional strain. This use may offer supportive therapeutic benefit by assisting with managing the intensity of these urges, which can help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview on Fluvoxamine

Eligibility and Restrictions for Use

Official Eligibility Rules for Favoxil

The eligibility to use Favoxil (Fluvoxamine Maleate) is strictly defined by regulatory documents, distinguishing between populations where use is approved, restricted, or absolutely prohibited.

Populations Excluded or Prohibited

Classification Who Cannot Use the Medicine (Contraindicated)
Absolute Prohibition Patients with known hypersensitivity to Fluvoxamine or any component.
Patients concurrently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing one.
Patients taking specific interacting drugs, including Tizanidine, Pimozide, Alosetron, or Thioridazine.

Age-Related Eligibility and Restrictions

Favoxil is approved for adults and for children and adolescents 8 to 17 years of age for the treatment of Obsessive-Compulsive Disorder (OCD) only. Use is not established for children under 8 years. Older adults (geriatric population) may use the medicine but require caution and slower dose adjustment due to a higher risk of conditions like hyponatremia (low sodium).

Conditional Use and Monitoring Required

Conditional use is mandatory for patients with certain medical conditions, including hepatic (liver) or renal (kidney) impairment, who require careful monitoring and a specified low starting dosage. The medicine is avoided in patients with unstable epilepsy and requires caution in those with a history of seizures, bleeding disorders, or mania.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Favoxil (fluvoxamine) can affect the levels of other medications in the body and increase the risk of specific side effects. It is essential to inform your healthcare provider of all prescription, over-the-counter, and herbal products you are taking.

Favoxil must not be combined with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, due to the high risk of Serotonin Syndrome. A 14-day washout period is required when switching between an MAOI and Favoxil. Co-administration is also contraindicated with Tizanidine, Thioridazine, Pimozide, Alosetron, and Ramelteon.

Favoxil is a potent inhibitor of certain liver enzymes (primarily CYP1A2), which can lead to increased concentrations and potentially toxic effects of co-administered drugs. Examples include Theophylline (requiring a dose reduction), Warfarin (requiring monitoring of bleeding time), Clozapine, and certain Tricyclic Antidepressants.

Concomitant use with other serotonergic agents (such as Triptans, Fentanyl, Lithium, or St. John's Wort) increases the risk of Serotonin Syndrome. Furthermore, combining Favoxil with blood thinners or anti-inflammatory drugs like NSAIDs or Aspirin may increase the risk of abnormal bleeding.

Mechanism of Action

Selective Modulation of Serotonergic Homeostasis

Favoxil's primary action is the selective reuptake inhibition of the Serotonin Transporter ( SERT) . This action immediately increases the concentration of serotonin (5- HT) in the synaptic space, which, over time, causes a chronic adaptation in receptor sensitivity and density. This slow, adaptive change results in the modulation of the functional state of neural circuits and defines the characteristic onset pattern of the pharmacological action.


Dual Action via Sigma-1 (sigma1R) Receptor Agonism

Fluvoxamine acts as an agonist of the sigma-1 receptor (sigma1R), an intracellular protein that functions as a molecular chaperone . This activation promotes the receptor's function, which is linked to increased neuronal resilience and synaptic integrity. This mechanism modulates cellular stress pathways, complementing the 5- HT action and contributing to the structural and functional adaptation of the central nervous system.

Dosage and Administration Information

Favoxil (Fluvoxamine Maleate) is administered orally in one of two official formulations: immediate-release film-coated tablets (25 mg, 50 mg, and 100 mg strengths) or extended-release capsules (100 mg and 150 mg strengths). The administration is non-restrictive regarding meals, as the medication can be taken with or without food. For proper use, extended-release capsules must be swallowed whole and should not be crushed, broken, or chewed. Tablets should also be swallowed whole with water.

The adult dosing regimen commences with a low initial dose of either 50 mg for tablets or 100 mg for extended-release capsules, typically taken once daily at bedtime. Dosing is procedural; adjustments are generally performed in 50 mg increments every four to seven days based on the therapeutic requirement, up to a maximum recommended daily amount of 300 mg.

The prescribed frequency pattern depends on the total daily dose. While doses up to 150 mg are often administered once daily, total daily doses exceeding 150 mg are typically given in divided doses, with the guidance specifying that the larger portion be administered at bedtime. Specific procedural adjustments are detailed for certain patient groups. For both older adults and individuals with hepatic impairment, the official protocols mandate starting at a lower dose and proceeding with upward dose adjustments more slowly, due to altered clearance.

When treatment is to be discontinued, the official use protocol requires a gradual dose reduction process rather than an abrupt stop.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Favoxil


Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Randomized Controlled Trials (RCTs) constitute a primary research approach exploring Favoxil in the context of Obsessive-Compulsive Disorder. These short-term trials were used in research to observe changes in symptom severity over a defined time interval, typically 10 to 12 weeks. The studies monitored adult, child, and adolescent populations diagnosed with OCD. Researchers evaluated symptom change by measuring scores on specialized tools, such as the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Systematic reviews and meta-analyses provide a broader perspective, with findings describing measurements of change in Y-BOCS scores, documenting the patterns of symptom evolution observed in the study populations. What remains uncertain is the long-term characterization of outcomes observed in the acute studies; follow-up durations were constrained, and long-term effects are not fully established.


Evidence for Use in Social Anxiety Disorder (SAD)

Favoxil was evaluated in a series of short-term Randomized Controlled Trials (RCTs) and systematic reviews that examined findings associated with conditions involving periods of heightened symptoms related to social situations. The research monitored changes in symptom severity in adult and pediatric populations diagnosed with Social Anxiety Disorder. Studies monitored outcomes reflecting daily functioning, primarily by measuring severity using instruments like the Liebowitz Social Anxiety Scale (LSAS). Findings describe patterns observed in the studies when comparing the treatment group to the placebo group. The evidence contributes to the broader evidence landscape, but comparative evidence is lacking, and some trials have reported mixed findings. Certainty remains low regarding the full range of individuals who may respond, especially those with complex, co-existing mental health conditions.


What is Still Uncertain About the Research

A critical gap in the research is the lack of robust, long-term, placebo-controlled data to characterize the full course of symptoms and stability beyond the first few months of use. Additionally, in areas beyond the core indications, research methods differed across studies, and sample sizes were modest. The research does not provide prediction of whether an individual will respond similarly to the group patterns observed in the studies. Subgroup findings are uncertain, and results apply only to the specific conditions and populations studied in the original research.

Frequently Asked Questions (FAQ)

Common questions about Favoxil (FAQ)


Q: How quickly does Favoxil typically start to show its effects and full benefit?

A: The official labeling describes the action of Favoxil as involving a chronic adaptation process within the brain's serotonin receptors. While the concentration of the medicine in the body may stabilize within about a week, the full therapeutic benefit is understood to be a gradual process associated with this slow, adaptive change. This characteristic onset pattern indicates that the effects are often not immediate.

Q: Can Favoxil be taken with alcohol?

A: Official product information advises avoiding the use of alcohol while taking Favoxil. This is consistent with general advice for psychotropic medications, as alcohol can potentially intensify certain effects of the medicine.

Q: Is Favoxil known to cause weight gain or weight loss?

A: Official documentation lists unusual weight gain or loss as a less common adverse effect. Studies also indicate that children and adolescents using the medicine may report weight loss more frequently than other changes in weight.

Q: Is there a risk of dependency when using Favoxil long-term?

A: Regulatory documents do not typically use the term 'dependency,' but they clearly state that treatment with Favoxil should be discontinued only by a gradual reduction of the dose. This process is mandatory to minimize the occurrence of potential withdrawal effects.

Q: Are there any vitamins or dietary supplements that interact with Favoxil?

A: According to the official product information, combining Favoxil with the herbal supplement St. John’s Wort increases the risk of a serious condition called Serotonin Syndrome. Official documents indicate that the supplement should be avoided, and all others should be reviewed with a healthcare professional before concurrent use.

Q: What should be done if someone misses a dose of Favoxil?

A: Official product information describes the procedure for managing a missed dose: it is to be taken as soon as remembered. However, if the time is close to the next scheduled dose, the instruction is that the missed dose should be skipped. The patient instruction is not to take two doses simultaneously to make up for the missed one.

Q: How long do most patients typically need to stay on Favoxil?

A: While early clinical trials were short-term, regulatory documents note that sustained therapy may be required. This aligns with the use of the medicine for long-term management in clinical practice, though the decision regarding continued use is typically reviewed periodically.

Q: What are the risks of using Favoxil during pregnancy or while breastfeeding?

A: Use of Favoxil during pregnancy is a decision made after a careful risk/benefit assessment by a healthcare provider. Regarding breastfeeding, limited data reviewed by the NIH suggests low levels in breastmilk. Use is generally considered possible in this context, but the infant should be monitored for adverse effects.

Q: Is it common to feel tired or dizzy after first starting Favoxil?

A: Official product labeling notes that somnolence (sleepiness or feeling tired) is classified as a Common side effect (occurring in 1% to <10% of patients). Dizziness is also reported by patients in clinical studies as a known occurrence.

Q: What happens when someone stops taking Favoxil?

A: Official use protocols require that the medicine is stopped using a gradual dose reduction process rather than an abrupt cessation. This tapering procedure is intended to minimize potential withdrawal effects, which may include anxiety, dizziness, confusion, or sensory disturbances.

Q: Can Favoxil be used for conditions other than its main approved indications?

A: Favoxil is officially approved by regulatory bodies for the treatment of Obsessive-Compulsive Disorder (OCD) in adults and in children between 8 and 17 years of age. The medicine’s authorized use is defined strictly by these specific conditions and populations.

Q: Does Favoxil interfere with the effectiveness of birth control pills?

A: According to official interaction data, Favoxil can increase the plasma levels of certain hormonal contraceptives (such as those containing levonorgestrel). This is due to the medicine inhibiting the CYP3A4 enzyme, which can affect the contraceptive's concentration.

Q: What is the reported half-life of Favoxil?

A: The mean plasma elimination half-life of Fluvoxamine (the active ingredient) at steady state is reported in official pharmacokinetic data to be approximately 15.6 hours in young, healthy adults. This measure may be longer for older adult patients.

Q: What are the signs of a possible allergic reaction to Favoxil?

A: The official label specifies that immediate medical attention is necessary if signs of a severe allergic reaction occur. These signs may include trouble breathing or swelling of the face, tongue, or throat.

Q: What is the success rate of Favoxil reported in clinical trials?

A: Studies and official information indicate that clinical findings are reported using classification scales rather than a single 'success rate' percentage. For instance, adult OCD studies showed that a total of 43% of the Favoxil group were classified as either Very Much Improved or Much Improved when compared to the placebo group.

Q: What are the official warnings about operating heavy machinery or driving while taking Favoxil?

A: Official warnings state that caution should be exercised when driving or operating heavy machinery until the effect of the medicine is known. This is because the drug is associated with potential side effects like drowsiness, dizziness, or sleepiness.

Q: Does Favoxil interact with over-the-counter pain relievers like Ibuprofen or Acetaminophen?

A: Official regulatory warnings note that combining Favoxil with nonsteroidal anti-inflammatory drugs (NSAIDs), such as Ibuprofen or Naproxen, or with Aspirin, may increase the risk of abnormal bleeding.

Q: Are there specific foods or drinks that should be avoided while taking Favoxil?

A: The medicine can generally be taken with or without food. However, official product information states that the intake of caffeine should be minimized, as Favoxil can increase caffeine's effects, potentially causing side effects like tremor and nausea.

How should Favoxil be stored and disposed of?

How to Store and Dispose of Favoxil

The storage and disposal of Favoxil (fluvoxamine maleate) must follow strict conditions outlined in regulatory labeling.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F). Excursions up to 30 C (86 F) are permitted.
Protection The product must be protected from light and high humidity; keep from freezing and excessive heat.
Container Keep in the original, tight, light-resistant container, and ensure the container remains tightly closed.

Handling and Disposal

Child Safety: It is mandatory to KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Disposal: Do not throw away outdated or unused medicine in household waste or wastewater. Patients are instructed to ask a healthcare professional or pharmacist how to properly dispose of any medicine that is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Favoxil found in:

A-Z Index: